Literature DB >> 26307567

Hypomyelination and developmental delay associated with VPS11 mutation in Ashkenazi-Jewish patients.

Shimon Edvardson1, Frank Gerhard2, Chaim Jalas3, Jens Lachmann2, Dafna Golan4, Ann Saada1, Avraham Shaag1, Christian Ungermann2, Orly Elpeleg1.   

Abstract

BACKGROUND: The genetic heterogeneity of developmental delay and cognitive impairment is vast. The endocytic network is essential for neural development and synaptic plasticity by regulating the sorting of numerous transmembrane proteins. Disruption of the pathway can lead to neuronal pathology. Endosomal biogenesis relies on two Rab proteins, Rab5 and Rab7, which bind to two hexameric tethering complexes, the endosomal class C core vacuole/endosome tethering complex (CORVET) and the late endosomal/lysosomal homotypic fusion and protein sorting complex (HOPS). Both complexes consist of four core proteins and differ by their specific Rab-binding proteins.
OBJECTIVES: To identify the molecular basis of a neurological disease, which consists of global developmental stagnation at 3-8 months, increasing appendicular spasticity, truncal hypotonia and acquired microcephaly, with variable seizure disorder, accompanied by thin corpus callosum, paucity of white matter and delayed myelination in eight patients from four unrelated Ashkenazi-Jewish (AJ) families.
METHODS: Exome analysis, homozygosity mapping and Mup1-GFP transport assay in mutant yeast.
RESULTS: Homozygosity for a missense mutation, p.Cys846Gly, in one of the endosomal biogenesis core proteins, VPS11, was identified in all the patients. This was shown to be a founder mutation with a carrier frequency of 0.6% in the AJ population. The homologous yeast mutant had moderate impairment of fusion of the late endosome to the vacuole in Mup1-GFP transport assay.
CONCLUSIONS: We speculate that in neuronal cells, impairment of fusion of the late endosome to the vacuole would attenuate the degradation of plasma membrane receptors, thereby underlying the progressive neuronal phenotype in our patients. The VPS11 p.Cys846Gly mutation should be added to the AJ carrier screening panel. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Neurology

Mesh:

Substances:

Year:  2015        PMID: 26307567     DOI: 10.1136/jmedgenet-2015-103239

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  19 in total

1.  A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy.

Authors:  Cas Simons; David Dyment; Stephen J Bent; Joanna Crawford; Marc D'Hooghe; Alfried Kohlschütter; Sunita Venkateswaran; Guy Helman; Bwee-Tien Poll-The; Christine C Makowski; Yoko Ito; Kristin Kernohan; Taila Hartley; Quinten Waisfisz; Ryan J Taft; Marjo S van der Knaap; Nicole I Wolf
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

2.  Biallelic truncating variants in ATP9A cause a novel neurodevelopmental disorder involving postnatal microcephaly and failure to thrive.

Authors:  Guido Vogt; Sarah Verheyen; Sarina Schwartzmann; Nadja Ehmke; Cornelia Potratz; Anette Schwerin-Nagel; Barbara Plecko; Manuel Holtgrewe; Dominik Seelow; Jasmin Blatterer; Michael R Speicher; Uwe Kornak; Denise Horn; Stefan Mundlos; Björn Fischer-Zirnsak; Felix Boschann
Journal:  J Med Genet       Date:  2021-06-18       Impact factor: 5.941

Review 3.  Recent trends in mucopolysaccharidosis research.

Authors:  Hiroshi Kobayashi
Journal:  J Hum Genet       Date:  2018-11-19       Impact factor: 3.172

4.  Mutations in RARS cause a hypomyelination disorder akin to Pelizaeus-Merzbacher disease.

Authors:  Michael Nafisinia; Nara Sobreira; Lisa Riley; Wendy Gold; Birgit Uhlenberg; Claudia Weiß; Corinne Boehm; Kristina Prelog; Robert Ouvrier; John Christodoulou
Journal:  Eur J Hum Genet       Date:  2017-07-26       Impact factor: 4.246

Review 5.  Hypomyelinating leukodystrophies - unravelling myelin biology.

Authors:  Nicole I Wolf; Charles Ffrench-Constant; Marjo S van der Knaap
Journal:  Nat Rev Neurol       Date:  2020-12-15       Impact factor: 42.937

6.  Bi-allelic VPS16 variants limit HOPS/CORVET levels and cause a mucopolysaccharidosis-like disease.

Authors:  Kalliopi Sofou; Kolja Meier; Leslie E Sanderson; Debora Kaminski; Laia Montoliu-Gaya; Emma Samuelsson; Maria Blomqvist; Lotta Agholme; Jutta Gärtner; Chris Mühlhausen; Niklas Darin; Tahsin Stefan Barakat; Lars Schlotawa; Tjakko van Ham; Jorge Asin Cayuela; Fredrik H Sterky
Journal:  EMBO Mol Med       Date:  2021-05-03       Impact factor: 14.260

7.  Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulation.

Authors:  Reini E N van der Welle; Rebekah Jobling; Christian Burns; Paolo Sanza; Jan A van der Beek; Alfonso Fasano; Lan Chen; Fried J Zwartkruis; Susan Zwakenberg; Edward F Griffin; Corlinda Ten Brink; Tineke Veenendaal; Nalan Liv; Conny M A van Ravenswaaij-Arts; Henny H Lemmink; Rolph Pfundt; Susan Blaser; Carolina Sepulveda; Andres M Lozano; Grace Yoon; Teresa Santiago-Sim; Cedric S Asensio; Guy A Caldwell; Kim A Caldwell; David Chitayat; Judith Klumperman
Journal:  EMBO Mol Med       Date:  2021-04-14       Impact factor: 12.137

8.  The second report of a new hypomyelinating disease due to a defect in the VPS11 gene discloses a massive lysosomal involvement.

Authors:  Konstanze Hörtnagel; Inge Krägeloh-Mann; Antje Bornemann; Miriam Döcker; Saskia Biskup; Heidi Mayrhofer; Florian Battke; Gabriele du Bois; Klaus Harzer
Journal:  J Inherit Metab Dis       Date:  2016-07-29       Impact factor: 4.982

9.  Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

Authors:  Manuel A Rivas; Brandon E Avila; Jukka Koskela; Hailiang Huang; Christine Stevens; Matti Pirinen; Talin Haritunians; Benjamin M Neale; Mitja Kurki; Andrea Ganna; Daniel Graham; Benjamin Glaser; Inga Peter; Gil Atzmon; Nir Barzilai; Adam P Levine; Elena Schiff; Nikolas Pontikos; Ben Weisburd; Monkol Lek; Konrad J Karczewski; Jonathan Bloom; Eric V Minikel; Britt-Sabina Petersen; Laurent Beaugerie; Philippe Seksik; Jacques Cosnes; Stefan Schreiber; Bernd Bokemeyer; Johannes Bethge; Graham Heap; Tariq Ahmad; Vincent Plagnol; Anthony W Segal; Stephan Targan; Dan Turner; Paivi Saavalainen; Martti Farkkila; Kimmo Kontula; Aarno Palotie; Steven R Brant; Richard H Duerr; Mark S Silverberg; John D Rioux; Rinse K Weersma; Andre Franke; Luke Jostins; Carl A Anderson; Jeffrey C Barrett; Daniel G MacArthur; Chaim Jalas; Harry Sokol; Ramnik J Xavier; Ann Pulver; Judy H Cho; Dermot P B McGovern; Mark J Daly
Journal:  PLoS Genet       Date:  2018-05-24       Impact factor: 5.917

10.  DNA methylation at birth potentially mediates the association between prenatal lead (Pb) exposure and infant neurodevelopmental outcomes.

Authors:  Christine A Rygiel; Dana C Dolinoy; Kelly M Bakulski; Max T Aung; Wei Perng; Tamara R Jones; Maritsa Solano-González; Howard Hu; Martha M Tellez-Rojo; Lourdes Schnaas; Erika Marcela; Karen E Peterson; Jaclyn M Goodrich
Journal:  Environ Epigenet       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.